HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) Supplementary data All Versions of this Article: JOE-08-0497v1 201/1/27    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Joglekar, M. Articles by Hardikar, A. Search for Related Content PubMed PubMed Citation Articles by Joglekar, M. Articles by Hardikar, A.

M Joglekar, Stem Cells and Diabetes Section, National Center for Cell Science, Pune, India
V Joglekar, Shree Seva Medical Foundation, Shirwal, India
S Joglekar, Shree Seva Medical Foundation, Shirwal, India
A Hardikar, Stem Cells and Diabetes Section, National Center for Cell Science, Pune, 411007, India

Correspondence: Anandwardhan Hardikar, Email: anand{at}isletbiology.com

Abstract

Objective: There have been considerable efforts in understanding the potential of human pancreatic endocrine cells to proliferate and transition into mesenchymal cell populations. Since rodent studies have demonstrated that mouse insulin-producing cells do not proliferate in vitro, a similar possibility has been considered for human islet endocrine cells. Considering the inherent differences in mouse and human pancreatic islets, we decided to assess the potential of human fetal pancreatic insulin-producing cells to proliferate in vitro.

Methods: We studied proliferative potential of human fetal pancreatic islet-derived populations from 2nd or 3rd trimester fetal pancreas and characterized the cells that grow out during their expansion. We have used 7 different approaches including in situ hybridization and immunostaining, quantitative estimation of multiple gene transcripts in populations as well as in single cells, clonal analysis of islet cells, assessment of heritable marks of active insulin promoter and thymidine analog-based lineage tracing.

Results: Our studies demonstrate that human fetal pancreatic insulin-producing cells proliferate in vitro to generate mesenchymal cell populations. Interestingly, epigenetic modifications that mark open chromatin conformation of insulin promoter region are retained even after a million fold expansion/proliferation in vitro.

Conclusion: These findings demonstrate that hormone-producing cells in pancreatic islets proliferate in vitro and retain epigenetic marks that characterize an active insulin promoter. Such in vitro-derived mesenchymal cells may be of potential use in cell-replacement therapy for diabetes.